Laurent Pharmaceuticals reaches agreement with US Cystic Fibrosis Foundation to increase Development Award to $US 5M
Laurent Pharmaceuticals Receives FDA and Health Canada Clearance to Initiate APPLAUD Phase 2 Clinical Study of LAU-7b for the Treatment of Cystic Fibrosis
Fenretinide, a chemotherapeutic agent for cancer, is water-insoluble and has a very low oral bioavailability. Hence, the objective was to deliver it as an injectable depot and improve the drug solubility and release behavior from poly(lactide-co-glycolide) (PLGA) microspheres by incorporating non-ionic surfactants with fenretinide. Enhancement of drug solubilization was observed with Brij 35 or 98, Tween 20 and Pluronic F127, but not Pluronic F68. Co-incorporation of Brij 98 with fenretinide significantly changed the microsphere morphology improved and fenretinide release profile.